initi overweight discount peer present buy opportun
initi coverag share agil overweight rate price
target line peer group median multipl ep
overweight rate reflect modest core top line growth synergi potenti
recov crude oil price off-set lab consolid concern histor high
growth region particularli china believ recent soft open buy
opportun look continu strong growth pharmaceut biotech
environment forens end market recoveri diagnost food safeti
area ga chromatographi
chromatography/mass spectrometri acceler growth already-healthi end
market agil anticip strong growth come biolog market
partial off-set small molecul pharma demand particularli china recov oil
price could lead upsid chemic energi end market model strong
growth diagnost genom group cc driven patholog
companion diagnost
 synergi believ manag solid job align entir
busi portfolio includ number tuck-in deal well spin-
keysight electron busi compani announc
share buy-back program highlight comfort balanc sheet believ
manag continu look accret deal well
recent soft spot life scienc appli market group saw weak
led manag lower china revenu expect
specif broad-bas slowdown small molecul pharma custom demand
particularli pronounc china given countri initi lower price gener
drug addit china food test market take longer anticip
recov histor level sign stabil china agil crosslab
group grow mid-teen despit recent disappoint china think
overal prospect remain solid long-term await recoveri food market
model align thought
invest thesi agil share significantli discount peer recent
soft expect persist particularli manag lower revenu
forecast china china still repres growth opportun compani
anticip recoveri food test biopharmaceut market
risk includ competit geograph exposur oil price research fund
agil conglomer focus life scienc diagnost environment forens
food test
ep
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
initi coverag share agil overweight rate price target
base in-lin peer earn multipl overweight rate reflect modest core top line
growth low mid-singl digit recov oil crude oil price synergi slightli off-set
lab consolid concern histor high-growth region particularli china
estim strong core growth come pharmaceut biotech environment
forens end market recoveri diagnost food safeti
compani launch new agil follow keysight electron measur
busi spin think good exampl manag vision synergist
busi model deliv improv sharehold valu compani sinc focus
core busi life scienc appli market group lsag diagnost genom
group dgg agil crosslab group acg
upsid estim could come high-growth region particularli china histor
region high grower recent slow lead manag lower
estim somewhat conservat opinion view estim conserv
previous high-growth region given continu tariff discuss brexit well
slow econom growth europ china addit upsid could come potenti
acquisit manag call two headwind china lead lower
expect anticip food market recoveri take longer expect specif
govern lab resum purchas histor level slow instrument sale
due china initi lower gener drug price chines govern decentr
food test contract lab initi improv countri food qualiti believ
lead long-term growth test volum chines biopharma side believ
nation goal lower gener drug price increas access gener drug chines
popul lead continu long-term stabil return growth agil small
nation bureau statist china
page
price target base ep estim line agil peer agil
share current trade discount peer median earn multipl believ
multipl line agil life scienc tool diagnost peer justifi given
expect growth in-lin median comp potenti upsid
page
diversifi ls dxrevenueebitdaev/ebitdaep cagrp/etickercompanypricemarket
agil form hewlett packard analyt system divis spin-off
headquart santa clara california current firm employe approxim
individu market product servic world-wide revenu
america europ asia pacif china account
follow agil spin-off electron measur busi keysight
agil realign busi segment life scienc appli market group
lsag diagnost genom group dgg agil crosslab group acg
agil lsag focus instrument reagent informat use cellular biolog
environment industri forens food analysi applic acg provid servic support
consum agil third parti instrument diagnost genom group
dgg focus predomin instrument reagent consum informat use
clinic diagnost anatom patholog laboratori
microarray
pcr qpcr instrument
molecular biolog reagent
autom electrophoresi
agil life scienc appli market group lsag creat instrument softwar
enabl custom examin biolog properti substanc microfluid
revenu shift lsag dgg appli figur retrospect
lsag gener total revenu increas
constant currenc year-over-year report reflect strong perform
pharmaceut model flat lsag growth cc growth report
agil life scienc appli market group market distribut product five end-
market includ revenu govern academ
revenu chemic revenu environment forens
revenu food safeti revenu geograph lsag revenu
america europ asia pacif
page
lsag acg end-
agil competit life scienc instrument softwar space includ
corpor shimadzu corpor
agil crosslab group acg offer consum servic support agil third
parti instrument end-market mirror life scienc appli market group lsag
environment forens food safeti servic support consum product
diagnost genom group includ within agil crosslab group agil
crosslab group divid core lab consum servic support refurbish
agil crosslab group gener revenu increas
constant currenc year-over-year report reflect strong end-market growth
acg revenu america europ asia pacif
model cc growth report cc growth report
agil consum revenu increas year-over-year
consum revenu agil manufactur market plethora consum
product includ gc lc column syring vial liner o-r nut tube lamp
mainten kit agil consum vendor-neutr mean compat
agil manufactur instrument allow agil receiv recur revenu
stream non-agil laboratori
agil lab servic support revenu increas year-over-year
lab servic support revenu agil offer product new instrument
instal well asset manag laboratori busi intellig monitor instrument
up-tim util servic histori remot monitor instrument recommend
specif applications/research manag put increas focu offer full
outsourc lab manag custom along consum busi agil
provid servic support agil non-agil laboratori
agil competit consum servic space includ danah corpor
along consum servic provid
lsag acg serv end-market broken group
govern academ chemic environment forens
market repres largest end-market agil
revenu grew year-over-year
long-term market growth per manag
manufacturing/qu control laboratori contract research organ contract
manufactur organ cmo agil product use throughout entir
drug/biolog product process includ drug/biolog discoveri research
manufacturing/qu control front-end discovery/research agil manufactur
distribut instrument consum reagent informat mass spectromet liquid
chromatograph molecular spectroscop x-ray crystallograph back-end
manufacturing/qu control agil manufactur distribut instrument consum
dissolut disintegr test
page
govern academ market smallest end-market agil
revenu govern academ revenu grew year-over-year market long-
term growth per manag govern academ custom typic
compris non-profit academ govern laboratori perform basic translat
consum informat servic found for-profit research laboratori clinic
research diagnost laboratori includ mass spectrometri liquid chromatographi
microarray
nation institut nih fund repres total agil revenu accord
manag howev believ pass-through effect impact overal
govern academ research spend found strong correl
nation institut nih fund agil revenu govern
academ end-market govern academ research
correl nih fund period nih fund got boost
expect singl digit growth trend continu propos budget cut
revenu includ life scienc revenu lsag acg segment
page
agil leader chemic end-market provid ga liquid chromatographi
spectroscopi system analyz suppli softwar analyz properti
substanc product agil chemic revenu grew year-over-year
long-term market growth rate chemic agil second largest
end-market agil revenu
agil chemic revenu partial expos price crude oil higher oil
price increas demand analyt instrument consum due increment
invest crude project regress analysi oil price vs agil chemic
revenu find oil price lead indic chemic
perform quarter exhibit exhibit correl
oil price lag quarter
oil price potenti recov reach one-year low januari
price breach day day move averag
respect given strong relationship regress demonstr
elev oil price could present upsid number price start rel flat
begin fallen sharpli due oversuppli concern
page
environment forens third largest end-market lsag acg fourth
overal largest end-market agil revenu environment forens
increas year-over-year long-term market growth primarili driven
environment invest china environment custom typic repres govern
univers commerci laboratori perform chemic pollut analysi air water soil
solid wast sampl forens custom repres govern non-govern
laboratori analyz evid crime scene investig perform enhanc
reaction drug test detect biolog chemic warfar agent due natur
test within custom group instrument manufactur stationari mobil
food safeti market agil second smallest end-market group
revenu food safeti increas year-over-year vs long-term market growth rate
long-term outlook driven overal increas global regul test food food
safeti custom typic repres qualiti control govern laboratori conduct
test import food product develop verif genet modifi product
qualiti control contamin pesticid packag
food safeti market impact period reorgan within china food ministri
china food regulatori bodi china govern histor ran food test creat
bottleneck process reorgan decentr test model enabl
privat lab perform test higher volum believ creat posit set-up
long term recogn short term neg china food ministri complet
transit expect food safeti market increas come quarter increas
adopt china privat lab partial slow continu central govern
agil life scienc appli market group lsag creat rang instrument
softwar custom includ liquid ga chromatographi mass spectrometri
spectroscopi softwar informat solut lab autom robot offer
chromatographi process separ two compon either liquid
chromatographi liquid sampl mixtur made compon inject
pressur liquid known-solv typic water acetonitril and/or methanol
pressur liquid solvent mobil phase forc sampl mixtur instrument column
stationari phase metal re-enforc cylind fill sorbent polym typic silica
sampl mixtur mobil phase acceler stationari phase column
mixtur compon separ base entiti physic reaction sorbent result
follow mixtur pass stationari phase sampl compon reach
detector vari time enabl calcul identifi quantifi sampl compon
wide varieti detector exist liquid chromatograph includ destruct mass
spectrometri atomic-emiss detect evapor light scatter non-destruct uv
absorpt diod array fluoresc refract index variable/multipl wavelength
page
ga chromatographi gc similar technolog liquid chromatographi although allow
separ ga instead liquid ga chromatographi volatil gaseou sampl
sampl boil point room temperatur inject pressur stream nobl
ga mobil phase carrier ga typic helium argon push gaseou sampl
mixtur column stationari phase mixtur pass column
individu compon react differ stationari phase elut absorpt
separ mixtur separ sampl exit stationari phase sampl
mobil phase pass detector informat cancel known nobl ga
identifi quantifi sampl liquid chromatographi plethora detector
nitrogen-phosphoru singl wavelength flame photometr detect mass spectrometri
agil market leader ga chromatographi gc market
mass spectrometri use detect identif quantif sampl
often partner front-end separ liquid ga chromatographi mass spectrometri
broadli use research increasingli clinic market includ prenatal/newborn
test drug abus metabolit test steroid endocrinolog microbiolog
atom spectroscopi use low-level detect part per million part per billion
identif quantif atom molecul use environment salt flue ga
 nanomateri nuclear materi food safeti drink water market
agil molecular spectroscopi busi segment two differ analysi method
ultraviolet visibl uv-vi fourier transform infrar ftir ultraviolet visibl spectroscopi
similar atom absorpt electromagnet radiat elev sampl excit
state detect energi pass-through level although uv-vi design molecular
compound vs metal atom fourier transform infrar also similar atom absorpt
although use infrar energi sourc
agil place increas focu softwar offer meaning differenti
custom agil creat openlab laboratori softwar suit scalabl open
softwar platform enabl custom analyz share scientif data throughout lab
agil acquir genohm laboratori manag softwar provid may
expand softwar informat offer
agil provid workflow solut custom rang robot autom liquid
handl agil recent launch magni prep fulli autom
librari prepar system sequenc agnost support non-agil librari
workflow solut enabl reproduc result quickli assay set minut
reproduc result one-day turnaround time manag design instrument
sequenc agnost begin ship june/juli believ complement
sever exist product sureselect target captur
agil crosslab provid suit consum product servic help custom run
lab offer vendor-neutr mean agil provid product
servic regardless custom use non-agil instrument
agil provid portfolio consum custom includ gc lc column
sampl prepar product custom chemistri lab instrument suppli
page
servic offer custom includ mainten troubleshoot repair train
instrument hardwar softwar servic includ start-up oper train
complianc support softwar servic well asset manag consult
servic help increas custom product
agil refurbish pre-own instrument sell budget-consci custom
agil acquir dako thu enter patholog diagnost market focus
matur economi north america western europ japan primarili patholog
lab specif larg lab hospit medic center refer lab
competit within diagnost genom busi includ roch group roch
ventana medic system inc danah corpor leica biosystem thermo fisher
scientif inc affymetrix agil also face regul
segment fda regulatori bodi place regul label manufactur
sale distribut product
diagnost genom busi provid product diagnost clinic end-
market agil third largest end-market revenu diagnost
genom increas constant currenc report line
long term market growth rate dgg revenu america
europ asia pacif model dgg cc growth
report cc growth report
agil dgg busi includ genom nucleic acid manufactur research
develop patholog companion diagnost reagent partnership biomolecular analysi
hematoxylin eosin stain common techniqu histopatholog assist
pathologist diseas diagnosi hematoxylin blue color stain cell nucleu
contain dna nucleoprotein organel contain rna acid eosin dye
pink stain cytoplasm cell intern sub-structur cell wall extracellular fiber
result sampl provid pathologist detail view tissu allow diseas
diagnosi base organ cell abnorm present tissu addit
 special stain exist silver stain period acid schiff prussian iron allow
greater detail identifi stain although use clinic
immunohistochemistri in-situ hybrid ish identifi advanc
stain techniqu although method perform routin clinic patholog
laboratori pathologist stain tissu sampl mixtur antibodi
antibodi bind specif protein antigen result stain tissu allow
pathologist identifi antibodi bind sampl thu target protein
present tissu use assess tissu benign malign grade
cancer identif cell type determin primari tumor locat companion diagnost
page
ish specif fluoresc situ hybrid fish fish probe fluorescence-
label complementari dna strand stain tissu sampl specif cdna strand
hybrid target sequenc contain within sampl fish probe
wash away sampl visual fluoresc microscop allow
pathologist determin dna make-up tissu tumor improv lab
diagnosi allow addit treatment techniqu companion diagnost
agil multipl product offer patholog product includ dakocoverstain
 dako omni autostain link artisan link special stain
multipl product fish/ish
agil offer rang polyclon primari antibodi analyz specif protein via antigen-
antibodi reaction product use turbidimetri nephelometri elisa
fluoresc molecul reagent use identifi specif cellular marker flow cytometri
agil offer rang flow cytometri reagent compat flow cytometri
companion diagnost use identifi drug best suit patient test
identifi drug would benefit advers reaction patient dako offer rang
assay target specif genet mutat thu rule
enrich research decreas amount sequenc need project
identifi target region genom interest research sequenc
relev region instead whole genom ultim save time decreas
agil provid microarray compar genom hybrid allow custom detect
copi number variat chromosom copi number chang microdelet
duplic agil provid wide rang microarray differ custom need
compani provid complet workflow solut cgh gene mirna express analysi
epigenet specialti profil analysi product includ microarray reagent hardwar
softwar agil microarray offer use pre- post-nat preimplant cancer
clinic research agil differenti microarray capabl qualiti oligo
pcr use amplifi dna detect amplif increas number copi
target dna sequenc target amplif sensit detect often
quantif qpcr sampl heat doubl strand dna
separ reaction cool either instrument
technician anneal attach oligonucleotid primer target region two
separ dna strand anneal sampl reheat trigger polymeras
chain reaction pcr synthes base elong onto singl dna strand therebi
doubl target dna strand process repeat multipl time via thermal cycl
achiev desir level dna
agil offer rang pcr qpcr instrument reagent use process
solut
pcr qpcr
instrument
page
electrophoresi
agil nucleic acid solut divis nasd manufactur develop
oligonucleotid api contract basi focu mid-to-larg scale product
special manufactur molecul pharmaceut purpos work custom
clinic trial commerci launch
nasd ad oligonucleotid manufactur facil frederick co
initi doubl capac manufactur nucleic acid activ pharmaceut ingredi agil
capac turn product line plant would scale new plant
initi capac facil schedul open facil
spoken specif custom project facil start produc commerci volum
end fiscal year revenu signific contribut
agil offer rang product throughout workflow includ librari prepar target
autom platform servic
autom electrophoresi separ techniqu protein peptid rna dna use
qualifi molecul size charg often use qc process often use nucleic
acid prepar product techniqu run system integr instrument data
process softwar reagent microfluid chip specif molecul question
page
agil focus complementari acquisit deploy sinc agil
acquir busi advanc analyt largest
acquisit agil acquir busi busi
agil also paid stake lasergen fulli
acquir bring total deploy
prior agil complet two notabl deal agil complet spin-off keysight
electron measur busi agil acquir dako danish cancer
diagnost compani
manag reiter commit primari growth driver go forward
continu focu bolt-on complementari acquisit align core
strategi aati lasergen instead transform deal dako manag
typic target privat space believ manag strong track-record
success integr tuck acquisit agil busi model
mike mcmullen chief execut offic mike mcmullen agil ceo sinc
serv presid presid chemic analysi
group head mike spearhead agil china
strategi creat agil crosslab group
robert mcmahon chief offic robert mcmahon recent join agil chief
financi offic cfo year prior robert
johnson johnson held variou financi leadership role within medic devic
jacob thaysen presid life scienc appli market group jacob thaysen
join agil part dako acquisit vice presid
raha presid diagnost genom group raha join agil
becam presid diagnost genom group previous vice
presid global market led go-to-market strategi launch
mark doak presid agil crosslab group mark doak join hewlett-packard co
agil predecessor held variou senior manag posit agil
spin-out mark head crosslab group sinc incept
page
agil beat top line quarterli guidanc midpoint last quarter
although consist beat bottom-lin quarterli guidanc
ep estim high end manag guidanc
model total revenu agil life scienc appli
market group lsag model flat constant currenc growth report
estim constant currenc growth report agil
crosslab group acg anticip diagnost genom group dgg growth
constant currenc report model constant currenc
growth total revenu estim core lsag growth driven pharma
 biotech environment forens end market estim core acg growth
driven pharma biotech environment forens estim core dgg
growth driven diagnost clinic pharma biotech end market
end-market estim pharmaceut growth academ
govern growth chemic growth environment forens
increas food safeti declin diagnost clinic growth
model growth academ govern
growth chemic growth environment forens increas
food safeti recoveri growth diagnost clinic growth
model gross margin expans year-over-year
model ep respect
agil net cash posit end cash equival
debt model oper cash flow translat free
cash flow per share forecast oper cash flow free cash
flow per share
page
agil compet broad rang segment face sever competitor includ bruker
div abbott lab molecular dx roch molecular tissu dx
competit product launch industri innov repres risk agil busi well
forward project
agil signific exposur geograph segment revenu america
europ asia pacif total revenu china agil
exposur variou economi across globe chang within economi
geograph segment prevent risk agil project
agil also signific exposur foreign exchang agil subject foreign exchang
fluctuat could significantli impact financi result
mani agil life scienc diagnost product requir regulatori approv fda
ce sfda prior commerci later expect regulatori product approv well
regulatori concern fda warn letter repres risk futur product launch time-
line exist product addit agil sell product across globe multipl
end-market chang global regul end market impact long-term
growth rate segment impact agil perform segment
agil perform govern academ strongli tie research fund
decreas global research fund could neg impact agil perform end-
page
million
life scienc appli market lsag
diagnost genom dgg
good sold
provis incom tax
good sold
research develop
compani report piper jaffray co up-to-d compani disclosur inform pleas visit http //www piperjaffray com/researchdisclosur
